TY - JOUR
T1 - Hodgkin's Disease
AU - Perez, Edith A.
AU - Rosenthal, Seth A.
AU - Devita, Vincent T.
AU - Hubbard, Susan Molloy
PY - 1993/7/29
Y1 - 1993/7/29
N2 - To the Editor: In their review of drug therapy for Hodgkin's disease (Feb. 25 issue),1 DeVita and Hubbard cite two trials conducted to compare chemotherapy alone with radiotherapy alone as treatment for stage I or II Hodgkin's disease2,3. They stated that both trials demonstrated that “combination therapy was as effective as radiotherapy.” The overall survival in the study by Biti et al.,2 with a median follow-up of eight years, however, was significantly higher among patients treated with radiotherapy than among those treated with chemotherapy (93 percent vs. 56 percent, P<0.001). Furthermore, the survival among patients who relapsed after…
AB - To the Editor: In their review of drug therapy for Hodgkin's disease (Feb. 25 issue),1 DeVita and Hubbard cite two trials conducted to compare chemotherapy alone with radiotherapy alone as treatment for stage I or II Hodgkin's disease2,3. They stated that both trials demonstrated that “combination therapy was as effective as radiotherapy.” The overall survival in the study by Biti et al.,2 with a median follow-up of eight years, however, was significantly higher among patients treated with radiotherapy than among those treated with chemotherapy (93 percent vs. 56 percent, P<0.001). Furthermore, the survival among patients who relapsed after…
UR - http://www.scopus.com/inward/record.url?scp=0027250371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027250371&partnerID=8YFLogxK
U2 - 10.1056/NEJM199307293290515
DO - 10.1056/NEJM199307293290515
M3 - Letter
C2 - 8321272
AN - SCOPUS:0027250371
SN - 0028-4793
VL - 329
SP - 361
EP - 362
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 5
ER -